David Spellman
Keine laufenden Positionen mehr
Vermögen: - $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
LeAnne Zumwalt | F | 65 | 3 Jahre | |
Ronald Frieson | M | 65 | 3 Jahre | |
Willard Dere | M | 70 | 6 Jahre | |
Tracey Vetterick | F | - | 2 Jahre | |
Meredith Bowman | F | - | 2 Jahre | |
Carolyn Rucci | F | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jason Amello | M | 55 | 7 Jahre | |
James Ahlers | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 17 Jahre |
Raymond T. Keane | M | 65 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 Jahre |
Maxine Gowen | M | 66 | 7 Jahre | |
Violetta Cotreau | F | 51 | 2 Jahre | |
Sarah Carmody | F | - | 4 Jahre | |
Elaine Jones | M | 69 | 3 Jahre | |
Sara Nayeem | M | 75 | 6 Jahre | |
Mark Enyedy | M | 60 | 3 Jahre | |
Michael Heffernan | M | 59 | 4 Jahre | |
David Noskowitz | M | - | 2 Jahre | |
James Rosenthal | M | 70 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 3 Jahre |
Donald Bergstrom | M | 52 | 4 Jahre | |
Dirk Huebner | M | 61 | 2 Jahre | |
Dell Faulkingham | M | 51 | - | |
Erin Colgan | F | 43 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 Jahre |
Robert Copeland | M | - | 5 Jahre | |
Kristie Wagner | F | 57 | 8 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 12 | 50,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David Spellman
- Persönliches Netzwerk